Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Adseverin: A novel cisplatin‐resistant marker in the human bladder cancer cell line HT1376 identified by quantitative proteomic analysis

4 Jan 2012

Abstract excerpt

Cisplatin is currently the most effective antitumor agent available against bladder cancer. However, a majority of patients eventually relapse with cisplatin-resistant disease. Chemoresistance thus remains a major obstacle in bladder cancer therapy. To clarify the molecular mechanisms underlying cisplatin resistance in bladder cancer, we established a cisplatin-resistant subline from the human bladder cancer cell...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Bladder and Urothelial Cancer Treatments
Share to Drug Transport and Resistance Mechanisms
Share to Glycosylation and Glycoproteins Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 22265592
DOI: 10.1016/j.molonc.2011.12.002

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Adseverin: A novel cisplatin‐resistant marker in the human bladder cancer cell line HT1376 identified by quantitative proteomic analysisPMID 22265592Read ↗

Upregulated expression of BCL2, MCM7, and CCNE1 indicate cisplatin-resistance in the set of two human bladder cancer cell lines: T24 cisplatin sensitive and T24R2 cisplatin resistant bladder cancer cell linesSemantic proximity Read ↗

Cisplatin resistance driver claspin is a target for immunotherapy in urothelial carcinomaSemantic proximity Read ↗

Gemcitabine/Cisplatin Treatment Induces Concomitant SERTAD1, CDKN2B and GADD45A Modulation and Cellular Changes in Bladder Cancer Cells Regardless of the Site of TP53 Mutation.Semantic proximity Read ↗

Differential Protein Expression Profiling by iTRAQ-Two-dimensional LC-MS/MS of Human Bladder Cancer EJ138 Cells Transfected with the Metastasis Suppressor KiSS-1 GeneSemantic proximity Read ↗

EHHADH contributes to cisplatin resistance through regulation by tumor-suppressive microRNAs in bladder cancerSemantic proximity Read ↗

IMP2 drives chemoresistance by repressing cisplatin-induced apoptosis and ferroptosis via activation of IPO4 and SLC7A11 under hypoxia in bladder cancerSemantic proximity Read ↗

NPEPPS is a novel and druggable driver of platinum resistanceSemantic proximity Read ↗

Mitochondrial Proteomic Analysis of Cisplatin Resistance in Ovarian CancerSemantic proximity Read ↗

Nuclear translocation of ISG15 regulated by PPP2R2B inhibits cisplatin resistance of bladder cancerSemantic proximity Read ↗

Identification of proteins differentially expressed in adriamycin-resistant (pumc-91/ADM) and parental (pumc-91) human bladder cancer cell lines by proteome analysisSemantic proximity Read ↗

Quantitative proteome analysis of multidrug resistance in human ovarian cancer cell lineSemantic proximity Read ↗

S-Palmitoylation as a Functional Regulator of Proteins Associated with Cisplatin Resistance in Bladder CancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.